Abstract The fludarabine plus cyclophosphamide (FC) regimen was reported to be superior to chlorambucil or fludarabine alone in terms of complete response (CR), overall response (OR) and progression-free survival (PFS) in previously untreated patients with chronic lymphocytic leukaemia (CLL). In the present study, we compared the efficacy and toxicity of FC administered through oral and intravenous route in 65 untreated patients affected by advanced CLL. No statistical differences were noticed between the two routes of administration in terms of OR, PFS, time to re-treatment (TTR) and overall survival (OS) of analysed patients. We also assessed the influence on the clinical outcome of the mutation status of the immunoglobulin variable region heavy chain (IgVH) gene, of the cytogenetic abnormalities and of the expression of ZAP70 and CD38 in patients' primary samples. Among the 58 evaluable patients, 31 (53%) achieved a CR and 18 (31%) a partial response. The median PFS was 35 months, median TTR was 42 months and median OS was not reached after 45 months (range, 1-161). A significantly lower OR rate was noticed in patients with high-risk cytogenetic abnormalities (del 17p, del 11q). In this study, high-risk cytogenetic abnormalities and unmutated IgVH genes were independent predictors of TTR. These results underline the importance of biological stratifications in front-line treatment of CLL patients. We confirm that FC is an effective regimen with mild toxicities; it could be recommended for patients with low-risk biological parameters who represent, in our experience, about 30% of the total.
Introduction
The purine analogue fludarabine inhibits the repair of DNA interstrand cross-links caused by alkylating agents [1, 2] . The synergistic effect between fludarabine and cyclophosphamide prompted investigation of a combined regimen of the two drugs for the treatment of patients affected by CLL.
Several studies, including two randomized trials, demonstrated that combined administration of fludarabine and cyclophosphamide (FC) is superior to other standard treatments for CLL, leading to the wide acceptance of this protocol as a front-line therapy in patients with advanced disease [3] [4] [5] [6] .
Recently, a randomized controlled trial comparing FC and FC plus Rituximab (FCR) showed an improved overall response (OR) rate, progression-free survival (PFS) and overall survival (OS) in patients receiving immunochemotherapy, and FCR can be considered the new standard for first-line treatment of physically fit CLL patients [7] . Moreover, the same trial showed that the effect of FCR vs FC in terms of OR rate is not improved in patients with mutated immunoglobulin variable region heavy chain (IgVH) and standard risk fluorescent in situ hybridization (FISH), suggesting that biological risk stratification may be necessary to determine the optimal first-line treatment in individual patients [8] . FCR also significantly improved PFS in previously treated CLL [9] .
We conducted a multicentre retrospective study to detect the efficacy and safety of FC as a front-line therapy of CLL, comparing two different schedules of treatment. In an effort to understand the impact of the molecular prognostic features on response and outcome, we studied the influence of the IgVH mutation status, interphase cytogenetic abnormalities, and expression of ZAP-70 and CD38 on the OR rate, progression free survival, time to re-treatment (TTR) and OS.
Materials and methods

Patients and treatment
This multicentre retrospective study included previously untreated patients with progressive CLL defined according to the National Cancer Institute criteria [10, 11] . Patients with previous episodes of autoimmune haemolytic anaemia or positive direct/indirect Coombs test were excluded. The study was approved by the internal ethical committee at our institution and all patients provided written informed consent.
Biological status of enrolled patients was tested at diagnosis or before starting treatment in all cases.
Thirty eight patients received oral fludarabine (30 mg/m 2 ) and oral cyclophosphamide (250 mg/m 2 ) and 27 patients received intravenous fludarabine (25 mg/m 2 ) and intravenous cyclophosphamide (250 mg/m 2 ); both treatments were administered for three consecutive days every 4 weeks for six cycles.
Patients receiving the oral formulation (os) or the intravenous administration (iv) were not hospitalized.
Patients receiving the oral or intravenous route in this study were randomly chosen. A slight reduction of the total dose of oral FC was adopted according to the previous data from our institution [12] .
Prophylaxis against herpes zoster and pneumocystis carinii was provided by the administration of acyclovir 800 mg tid and trimetoprim-sulfametoxazol 960 mg bid for two consecutive days every week, during the entire treatment period and 2 months after. Administration of G-CSF was used independently for grade IV neutropenia from the onset of fever. Treatment was delayed for up to 2 weeks in case of grade III-IV cytopenia, at day 28 of each cycle. Once the cytopenia was reduced to grade I or II, treatment was reinstituted with a 25% dose reduction of both drugs for all subsequent cycles. A further 25% dose reduction was performed in the case of grade III-IV cytopenia in subsequent cycles. Treatment was discontinued in case of progressive disease, autoimmune haemolytic anaemia, autoimmune thrombocytopenia or pure red cell aplasia (PRCA).
Study end points
The efficiency of the treatment was assessed according to the National Cancer Institute Working Group response criteria [10, 11] . PFS, TTR and OS were defined from the date when therapy was started to the date of progression, re-treatment and death or last follow-up, respectively.
The primary end point of the study was the response rate and safety of oral and intravenous treatment with fludarabine and cyclophosphamide. The secondary end point was an evaluation of the influence of biological parameters on OR rate, PFS, TTR and OS.
Fluorescent in situ hybridization
Interphase FISH studies were performed according to the manufacturer's instructions on peripheral blood samples using a set of four commercial probes (Abbott, WiesbadenDelkenheim, Germany) [13] . An alpha satellite DNA probe CEP12 directly labelled with SpectrumOrange was used to detect aneuploidy of chromosome 12. LSI p53 together with CEP17 alpha satellite DNA probes labelled with SpectrumOrange and SpectrumGreen, respectively, were used to evaluate chromosome deletion at 17p13.1. LSI RB and LSI ATM, both labelled with SpectrumOrange, were used to detect chromosome deletion at 13q34 and 11q22-23, respectively. Prior to hybridization, the slides were dehydrated with three ethanol washes (70%, 85%, and 100%) and air dried. A 10-μL probe mixture was added to each slide, and the slides were covered with a coverslip. The slides were then denatured using a Vysis Hybrite set (Vysis Inc.) at a melting temperature of 75°C for 5 min and then hybridized at 37°C overnight. The coverslips were removed, and the slides were washed for 2 min in 0.4X saline sodium citrate (SSC) at 73°C and then in 2X SSC at room temperature for 2 min. The nuclei were counterstained with 46-diamindino-2-phenylindole dihydrochloride and were cover again with a coverslip. A minimum of 200 consecutive, qualifying, interphase nuclei were analysed using a Zeiss AxiosKop 2 plus fluorescent microscope. The normal cutoff value was established by analysing ten peripheral blood samples from normal blood subjects.
IgVH gene mutational analysis
Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll gradient centrifugation (Amersham Biosciences, Uppsala, Sweden). Total cellular RNA was isolated from PBMCs using the Trizol reagent (Invitrogen) according to the manufacturer's instructions. RNA was reverse transcribed using random hexamers and then amplified with the polymerase chain reaction (PCR) using a degenerate VH framework 1 (FWR1) primer in combination with Cμ, Cγ and Cα reverse primers. Samples that failed to amplify with these combinations were amplified with a mixture of forward primers complementary to leader sequences of the VH family one to six. The PCR products were purified with the QIAquick PCR purification kit (Qiagen, Valencia, CA) and either sequenced directly or cloned with the PCR Cloning Plus kit (Qiagen) [14] . Sequencing analysis was performed with the BigDye Terminator v3.1 Cycle Sequencing kit on an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA). Candidate germ line genes were assigned by searching the VBASE directory. Sequences with less than 2% differences from germ line VH sequences were considered unmutated.
Flow cytometry
Fifty microliters of whole blood in EDTA containing approximately 5×10 5 cells were incubated at room temperature in the dark for 20 min with CD3 PE-Cy5, CD56 PECy5, CD5 FITC and CD19 PE-Cy7 to identify surface antigens. After incubation, samples were centrifuged at 1,500 rpm for 5 min. Cell pellets were resuspended in 100 μL of fixation medium A (Caltag Laboratories, Burlingame, CA, USA) and incubated at room temperature in the dark for 15 min. Then cells were pelleted again at 1,500 rpm for 5 min, resuspended in 100 μL of permeabilization medium B (Caltag Laboratories) and incubated with the ZAP-70 monoclonal antibody at room temperature in the dark for 1 h. The ZAP-70 antibody was Rphycoerythrin conjugated (clone 1E 7.2, Caltag Laboratories). Samples were washed twice by centrifugation at 1,500 rpm for 5 min and resuspended in 500 μL of phosphate-buffered saline. Finally, 1×10 4 fixed cells were analysed by flow cytometry (BD FACSCanto, Becton Dickinson) using the gating strategy described by Crespo et al. [15] . Cases expressing more than 20% ZAP-70 positive CLL B-cells were defined as positive.
CD38 analysis was performed in the setting of routine cellular immunophenotyping using PE-conjugated anti-CD38 from Becton Dickinson (San Jose, CA). Peripheral blood mononuclear cells, separated from heparinised venous blood by density gradient centrifugation (Histopaque-1077, Sigma Diagnostics, St. Louis, MO) were analysed for surface expression of CD19/CD5/CD38 and CD19/CD5/ CD23 by triple colour immunofluorescence. Isotypematched negative controls were used in all the assays to determine positive from negative results. Flow cytometric analyses were performed on a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems) equipped with argon and red diode lasers. The CellQuest software system (Becton Dickinson Immunocytometry Systems) was used to acquire and to analyse data. Cases expressing more than 30% CD38 positive CLL B-cells were defined as positive [16] .
Statistical analysis
First we analysed the impact of the two different routes of administration (oral/iv) on the following outcomes: OR rate defined as achievement of complete response (CR), partial response (PR), and nodular PR; PFS defined as the time interval from the first day of treatment until disease progression; TTR calculated from the first day of treatment until initiation of a new treatment; OS time, calculated from the first day of treatment until death from any cause. For non-responders and progressive disease, date of progression was when no response or progressive disease was recorded.
The following parameters were used: sex, age (<65 years vs >=65 years), Binet stage (B/C), cytogenetic abnormalities (high risk HR vs standard risk SR cytogenetics), IgVH mutational status, expression of ZAP-70 and CD38. We chose to consider patients with 11q deletion and 17p deletion together as a high-risk cytogenetic group because of the small number of patients with these abnormalities (eight patients with del 17p and 7 patients with del 11q). Response to treatment was also included for PFS/TTR/OS outcomes.
The Chi-square test was used to analyse the categorical variables. Univariate survival analysis was performed using the Kaplan-Meier method and Logrank test. The Cox's proportional hazard model and the logistic regression model were used to test the association of the covariates with outcomes of PFS/TTR/OS and OR rate, respectively. Only variables that, in the univariate analysis, reached a P value<0.25 were included in the model. The models were built using the backward stepwise (Wald) procedure.
The results are expressed as hazard ratios (HRs) and 95% confidence intervals (CI95%). Statistical analysis was performed using the Statistical Package for Social Sciences, release 16.0 for Windows. A P value less than 0.05 was considered significant.
Results
Patient characteristics
Sixty five previously untreated patients with progressive CLL from three different Italian institutions were enrolled in the study. Thirty eight patients received oral schedule treatment at the Catholic University Medical Centre; 27 patients were enrolled from a medical centre that had adopted an iv schedule of FC combination: 15 patients were treated at the Viterbo Hospital and 12 patients at the San Giovanni Rotondo Hospital. Median time between the diagnosis and the beginning of therapy was 27 months (range, 1-137). Forty eight patients were male and 17 were female with a median age of 65 years (range, 44-78 years). Fifty two patients were in stage B/II, four in stage C/III and nine in stage C/IV. Thirty three patients had not mutated and 18 had mutated IgVH genes; in 14 patients the mutation status was not determined. Fifteen patients (23%) had the "high risk" cytogenetic abnormality del (11q22.3) or del(17p13.1). Twenty eight patients expressed ZAP-70 (cutoff, 20%) and 23 patients were CD38 positive (cutoff, 30%) ( Table 1) .
Response
Fifty eight patients were evaluable for response to treatment. Seven patients did not complete the planned treatment: two of them because of onset of immune thrombocytopenia that developed after two and four cycles, one because of PRCA that developed after the first cycle and one because of skin toxicity that developed after two cycles. The other three patients died during treatment: two from pneumonia that occurred in the setting of grade IV neutropenia after the first and second cycle, respectively, and one from sudden cardiac death after three cycles of therapy.
Thirty one patients (53%) obtained a CR and 18 (31%) a partial response, with an OR rate of 84%. Four patients showed stable disease and five patients experienced disease progression after two, three, four (two patients) and six cycles, respectively. No statistical differences were observed when comparing the OR in the group of patients treated with iv FC (83% OR) and those treated with oral FC (85% OR).
The high-risk cytogenetic-patients group included eight patients with del 17p and seven with del 11q. We noticed four responses to the treatment in each cytogenetic alteration, even if three of the four 17p deletion patients showed less than 20% positive cells.
Univariate analysis showed cytogenetic abnormalities as the only factor influencing the OR rate (P=0.016). CD38 expression and stage of disease were also included in the multivariate model because of a P value<0.25 in the univariate analysis, but only high-risk cytogenetic abnormalities were identified as an independent prognostic parameter (HR, 0.093; CI, 0.015-0.580). The IgVH, ZAP-70 and CD38 categories did not show statistical differences in terms of the OR rate (Table 2) .
PFS, TTR, and OS
The median PFS was 35 months (range, 2-118). In the univariate analysis, response to the treatment was significantly associated with PFS (P<0.001). The IgVH mutation status (P=0.132) and FISH (P=0.058) were also included in the multivariate model because of a P value<0.25, but only the response to therapy was identified as an independent prognostic parameter ( Table 2) .
The median TTR was 42 months (range, 2-118). Response to the treatment (P<0.001), IgVH mutation status (P=0.026), cytogenetic abnormalities (P=0.007) and age (P=0.25) were investigated in the multivariate model; response to the treatment, IgVH and cytogenetic abnormalities emerged as independent prognostic factors ( Table 2 ; Figs. 1, 2) .
The median OS was not reached after 45 months (range, 1-161). During the study period, 19 patients died.
In univariate analysis only response to the treatment achieved a statistically significant value (P<0.001); whereas, response to treatment and age emerged as independent prognostic factors from the multivariate analysis (Table 2) . Haematological and extra-haematological toxicity
Twelve patients developed grade III and 21 patients developed grade IV neutropenia (37% after iv FC and 29% after oral FC). Two of these patients, both of them from the iv FC arm, died because of pneumonia after the first and second cycle of therapy. Three patients developed grade III or grade IV anaemia that required red blood cell transfusions. Two patients developed immune thrombocytopenia after the second and fourth cycle and one patient developed pure red cell aplasia after the first cycle, which regressed after treatment with steroids and Rituximab. As for extra haematological toxicity, nausea was reported by 18 patients and eight of them also experienced vomiting; as expected, these complications were predominantly observed in the oral FC group. One patient developed fever of unknown origin after the first cycle of chemotherapy, which spontaneously resolved without hospitalization. One patient showed severe skin toxicity due to chemotherapy and discontinued treatment after two cycles. One patient died after three cycles of therapy from sudden cardiac death due to congenital abnormalities of the coronary arteries discovered during autopsy (Table 3) .
Discussion
A large multicenter study recently demonstrated that fludarabine plus cyclophosphamide is superior to chlorambucil or fludarabine alone as front-line treatment of CLL with respect to CR, OR and PFS [4] . In addition, FC was found to be superior to chlorambucil or fludarabine alone in all age groups, including patients older than 70 years, suggesting that FC can be considered the standard treatment for chronic lymphocytic leukaemia. The results of this study confirmed our preliminary data and other published studies [3] [4] [5] [6] 12 , 17] regarding the efficacy and safety of fludarabine plus cyclophosphamide as front-line therapy in patients affected by chronic lymphocytic leukaemia (Table 4) . Table 4 shows a similar response to therapy among five data series on the FC regimen, even if the dose, timing and route of administration were different in the reported studies. The table also underlines differences in PFS between different studies that could be explained by a lower cumulative dose of chemotherapy or a different schedule of administration. No comparison of TTR and OS is possible because of unavailability of comparable data.
In our study we did not detected any significant difference in the clinical outcome between the iv FC and the oral FC groups, even though the total dose of fludarabine and cyclophosphamide was higher in the iv FC group. Patients who received oral combination were previously reported in our published series. In that series, we adopted a total dose of FC slightly decreased compared to other published studies in order to reduce the side effects of the drugs and to avoid hospitalization in elderly patients with comorbidities. The higher iv dose could explain why patients from the iv FC group experienced more often grade III/IV neutropenia and more severe infections, including two fatal pneumonias. On the other hand, nausea and vomiting occurred more often among patients receiving oral FC.
Results from a large non randomized trial of FCR and preliminary results of a randomized, controlled trial comparing FC vs FCR showed an improved response rate and PFS in patients who received the immunochemotherapy regimen, so FCR has become the new standard first-line treatment for physically fit CLL patients [7, 18] . The same study reported that the effect of FCR vs FC on the OR rate is not higher in patients with IgVH mutated CLL and standard risk FISH [8] . In the monoclonal antibody era, when the association with chemotherapy shows certain benefits on clinical outcome but also more haematological and extra haematological toxicities, a stratification of the biological risk of patients prior to treatment should be considered. In our series, we found that the 'high risk' cytogenetic abnormalities are independent predictors of a lower OR rate as well as a shorter TTR. In addition, unmutated IgVH genes are significantly associated with a shorter TTR, whereas expression of CD38 and ZAP-70 has no significant impact on clinical outcome.
As expected, response to treatment was an independent predictor of longer PFS, TTR and OS, while age was predictive of longer OS in our study. Biological risk stratifications demonstrated that patients with "high-risk" cytogenetic abnormalities and germ line IgVH genes have a shorter TTR following FC chemotherapy, suggesting that high-risk untreated younger patients affected by progressive CLL should be candidates to receive chemoimmunotherapy. Conversely, a consistent group of low-risk CLL patients emerged from the biological stratification. These patients display mutated IgVH and a standard-risk FISH and they respond to FC with a high OR rate and a prolonged TTR. A good compliance to treatment and the strong tolerability exhibited by this substantial proportion of patients argue that they could benefit from FC alone. FCR can be also employed to treat these patients, but haematological and extra- 
